A novel approach to arterial thrombolysis

Area of Science:

• Cardiovascular Research
• Thrombolysis Therapy
• Pharmacology

Background:

• Acute myocardial infarction (AMI) reperfusion therapy remains suboptimal in ~50% of patients despite potent thrombolytics.
• Thrombolytic therapy is limited by bleeding risks associated with higher concentrations and adjunctive agents.
• Thrombin-activatable fibrinolysis inhibitor (TAFI) activation attenuates clot lysis, representing a therapeutic target.

Purpose of the Study:

• To evaluate the efficacy of inhibiting activated TAFI (TAFIa) using potato tuber inhibitor (PTI) as an adjunct to tissue-plasminogen activator (tPA) in a rabbit arterial thrombosis model.
• To assess the impact of TAFIa inhibition on thrombolytic therapy outcomes and safety parameters.

Main Methods:

• A rabbit arterial thrombolysis model was utilized to compare tPA alone versus tPA with PTI.
• Thrombolytic efficacy was quantified by measuring time to patency, duration of patency, maximal blood flow, clot lysis percentage, clot weight change, and fibrin degradation product release.
• Hemodynamic and coagulation parameters (blood pressure, aPTT, TT, fibrinogen, alpha-2-antiplasmin) were monitored.

Main Results:

• Coadministration of PTI and tPA significantly improved tPA-induced thrombolysis compared to tPA alone.
• Key efficacy measures, including time to patency and clot lysis, were favorably impacted by the combination therapy.
• No adverse effects on blood pressure, coagulation times, fibrinogen, or alpha-2-antiplasmin levels were observed.

Conclusions:

• Inhibitors of TAFIa, such as PTI, represent a novel and effective adjunct to tPA for enhancing thrombolytic therapy.
• This approach improves clot lysis and vessel patency in AMI models without compromising safety.
• Targeting TAFIa offers a promising strategy to optimize reperfusion in acute myocardial infarction.